Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
J Anesth. 2019 Apr;33(2):197-208. doi: 10.1007/s00540-018-2597-2. Epub 2019 Jan 2.
Although many drugs or interventions have been studied to manage catheter-related bladder discomfort (CRBD), their comparative effectiveness is unknown. We attempted to assess the comparative effectiveness of the strategies to manage CRBD in patients undergoing urologic surgery including amikacin, solifenacin, darifenacin, butylscopolamine, dexmedetomidine, gabapentin, glycopyrrolate, ketamine, oxybutynin, resiniferatoxin, tolterodine, tramadol, caudal block, dorsal penile nerve block, lidocaine-prilocaine cream.
We performed an arm-based network meta-analysis including 29 trials with 2841 participants. Goodness of model fit was evaluated by deviance information criteria (DIC). The incidence of CRBD at 0, 1, and 6 h after surgery and the incidence of moderate to severe CRBD at 0, 1, and 6 h after surgery were compared.
Random effect model was selected according to DIC. Most of the drugs significantly decreased the incidence of CRBD except amikacin, tramadol at 0 and 1 h after surgery. Dexmedetomidine, solifenacin, caudal block, dorsal penile nerve block, resiniferatoxin, and gabapentin 1200 mg p.o. significantly decreased the incidence of CRBD at 6 h after surgery (gabapentin 1200: Odds ratio [OR] 0.02; SUCRA 95.6). Dexmedetomidine and tolterodine significantly decreased the incidence of moderate to severe CRBD at 0, 1, and 6 h after surgery (tolterodine at 6 h: OR 0.05; SUCRA 73.7).
Gabapentin was ranked best regarding the overall incidence of CRBD, while tolterodine was ranked best in reducing the severity of CRBD. However, a firm conclusion cannot be made from our analysis due to small-study number and heterogeneity regarding study setting and outcome measurement.
尽管已经研究了许多药物或干预措施来治疗与导尿管相关的膀胱不适(CRBD),但它们的相对有效性尚不清楚。我们试图评估在接受泌尿科手术的患者中管理 CRBD 的策略的相对有效性,包括阿米卡星、索利那新、达非那新、丁溴东莨菪碱、右美托咪定、加巴喷丁、格隆溴铵、氯胺酮、奥昔布宁、树脂毒素、曲马多、骶管阻滞、阴茎背神经阻滞、利多卡因-丙胺卡因乳膏。
我们进行了一项基于手臂的网络荟萃分析,包括 29 项试验,共 2841 名参与者。通过偏差信息准则(DIC)评估模型拟合的好坏。比较手术后 0、1 和 6 小时时 CRBD 的发生率以及手术后 0、1 和 6 小时时中度至重度 CRBD 的发生率。
根据 DIC 选择了随机效应模型。除了阿米卡星和手术后 0 和 1 小时的曲马多外,大多数药物都显著降低了 CRBD 的发生率。右美托咪定、索利那新、骶管阻滞、阴茎背神经阻滞、树脂毒素和口服加巴喷丁 1200mg 显著降低了手术后 6 小时时 CRBD 的发生率(加巴喷丁 1200:比值比 [OR] 0.02;SUCRA 95.6)。右美托咪定和托特罗定在手术后 0、1 和 6 小时时显著降低了中度至重度 CRBD 的发生率(托特罗定在 6 小时时:OR 0.05;SUCRA 73.7)。
加巴喷丁在总体 CRBD 发生率方面排名最佳,而托特罗定在降低 CRBD 严重程度方面排名最佳。然而,由于研究设置和结果测量的异质性,我们的分析无法得出确定的结论。